Agilon Health, Inc. (AGL) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Agilon Health, Inc. (AGL) stock forecast summary
On Oct. 14, 2026, AGL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4004 stocks scored that day.
Agilon Health, Inc. is a small-cap company with a market capitalization of $1.44B. It ranks number 5 by market capitalization among the 11 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast. Its D/E Ratio of 5.99x is the highest of the 9 peers that report one.
A per-ticker accuracy statistic for AGL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AGL included.
Follow AGL freeAGL price chart and AI forecast
How AGL ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Agilon Health, Inc. (AGL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
Valuation & Market
| Metric | AGL | Rank |
|---|---|---|
| Market Cap | $1.44B | 5/11 |
| P/B Ratio | 6.34x | 2/7 |
| EPS | $-14.27 | – |
| Book Value/Share | $13.55 | – |
| Revenue/Share | $352.57 | – |
| FCF/Share | $-5.06 | – |
Profitability & Margins
| Metric | AGL | Rank |
|---|---|---|
| ROE | -102.1% | 5/7 |
| ROA | -14.6% | 7/10 |
| ROIC | -110.9% | 7/8 |
| Operating Margin | -5.2% | 6/9 |
| Net Margin | -3.9% | 6/10 |
| EBT Margin | -4.3% | 6/10 |
| Tax Rate | -0.3% | – |
Financial Health
| Metric | AGL | Rank |
|---|---|---|
| Current Ratio | 1.08x | 8/11 |
| D/E Ratio | 5.99x | 1/9 |
| Financial Leverage | 6.99x | 1/9 |
| Interest Coverage | 5.7x | 5/12 |
| Working Capital | $106M | 4/11 |
Cash Flow
| Metric | AGL | Rank |
|---|---|---|
| Operating Cash Flow | -$72M | 11/11 |
| Free Cash Flow | -$85M | 7/7 |
| Capital Spending | -$13M | 3/7 |
| FCF/Sales | -1.4% | 7/7 |
| CapEx/Sales | 0.2% | 7/7 |
Operational Efficiency
| Metric | AGL | Rank |
|---|---|---|
| Asset Turnover | 3.72x | 1/9 |
| Receivables Turnover | 5.6x | 6/9 |
| Fixed Assets Turnover | 241.5x | 1/8 |
| Days Sales Outstanding | 65 days | 4/9 |
Income Statement
| Metric | AGL | Rank |
|---|---|---|
| Total Revenue | $5.92B | 2/9 |
| Operating Income | -$309M | 10/10 |
| Net Income | -$232M | 10/10 |
Dividend & Shareholder Information
| Metric | AGL | Rank |
|---|---|---|
| Shares Outstanding | 17M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.42B | 89.1% of assets |
| Cash & Short-term Investments | $107M | 6.7% of assets |
| Accounts Receivable | $1.06B | 66.6% of assets |
| Total Liabilities | $1.36B | 85.7% of assets |
AGL quarterly financials and insider trading
Agilon Health, Inc. (AGL) industry peers
Companies classified under the same SEC industry code as Agilon Health, Inc. (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| AGL Agilon Health, Inc. | ▶ | $1.44B |
| DVA Davita Inc. | ▲ | $11.62B |
| FMS Fresenius Medical Care Ag | ▼ | $5.89B |
| SHC Sotera Health Co | ▼ | $5.20B |
| PGNY Progyny, Inc. | ▶ | $2.10B |
| VMD Viemed Healthcare, Inc. | ▲ | $366M |
| PARK Park Dental Partners, Inc. | ▶ | $93M |
| MRAI Marpai, Inc. | ▲ | $86M |
| CCEL Cryo Cell International Inc | ▲ | $35M |
| PFHO Pacific Health Care Organization Inc | ▲ | $12M |
| MGRX Mangoceuticals, Inc. | ▶ | $8M |
| BRTX Biorestorative Therapies, Inc. | ▶ | N/A |
| NIVF Newgenivf Group Ltd | ▼ | N/A |
Where AGL sits on the market map
Agilon Health, Inc. (AGL) stock news
Loading...
Agilon Health, Inc. (AGL) stock forecast FAQ
What is the Agilon Health, Inc. (AGL) stock forecast?
On Oct. 14, 2026, AGL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4004 stocks scored that day.
How accurate are Agilon Health, Inc. stock predictions?
A per-ticker accuracy statistic for AGL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Agilon Health, Inc. forecasts updated?
Agilon Health, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Agilon Health, Inc.'s industry peers?
13 issuers in our coverage, AGL included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Davita Inc. (DVA), Fresenius Medical Care Ag (FMS), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Viemed Healthcare, Inc. (VMD), Park Dental Partners, Inc. (PARK).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.